BE1029004B1 - New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseases - Google Patents
New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseasesInfo
- Publication number
- BE1029004B1 BE1029004B1 BE20210007A BE202100007A BE1029004B1 BE 1029004 B1 BE1029004 B1 BE 1029004B1 BE 20210007 A BE20210007 A BE 20210007A BE 202100007 A BE202100007 A BE 202100007A BE 1029004 B1 BE1029004 B1 BE 1029004B1
- Authority
- BE
- Belgium
- Prior art keywords
- pharmaceutical formulations
- nervous system
- degenerative disorders
- glucosamine
- viral infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Er zijn farmaceutische formuleringen ontwikkeld, die bevatten verschillende eenvoudig metabolieten, om de biologisch activiteit van glucosamine, als metaboliet, preventief of therapeutisch optimaal te gebruiken bij degeneratieve aandoeningen van het zenuwstelsel, mentale stress en burn-out. Deze farmaceutische formuleringen bezitten ook een antivirale en antitumorale werking. Virus-geïnfecteerde cellen met glucosamine formuleringen produceren niet-infectieuze virale deeltjes en virale subeenheden die, eenmaal geïsoleerd, kunnen gebruikt worden als antigenen om vaccins te ontwikkelen. De farmaceutische formuleringen bevatten D-(+)-Glucosamine hydrochloride en een of meer van de volgende stoffen: D-galactose, malaat, lactaat, acetaat, arginine, glutamine, piruvaat, propionaat, ornithine, Ringer's lactaatoplossing.Pharmaceutical formulations containing various simple metabolites have been developed to optimally utilize the biological activity of glucosamine, as a metabolite, preventively or therapeutically in degenerative disorders of the nervous system, mental stress and burnout. These pharmaceutical formulations also possess antiviral and antitumor activity. Virus-infected cells with glucosamine formulations produce non-infectious viral particles and viral subunits that, once isolated, can be used as antigens to develop vaccines. The pharmaceutical formulations contain D-(+)-Glucosamine hydrochloride and one or more of the following: D-galactose, malate, lactate, acetate, arginine, glutamine, piruvate, propionate, ornithine, lactated Ringer's solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE20210007A BE1029004B1 (en) | 2021-01-11 | 2021-01-11 | New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE20210007A BE1029004B1 (en) | 2021-01-11 | 2021-01-11 | New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
BE1029004A1 BE1029004A1 (en) | 2022-08-08 |
BE1029004B1 true BE1029004B1 (en) | 2022-08-16 |
Family
ID=78819201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE20210007A BE1029004B1 (en) | 2021-01-11 | 2021-01-11 | New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseases |
Country Status (1)
Country | Link |
---|---|
BE (1) | BE1029004B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100291240A1 (en) * | 2009-05-13 | 2010-11-18 | Wyeth Llc | Method to Stabilize a Dietary Supplement to Facilitate Joint Health in Humans |
-
2021
- 2021-01-11 BE BE20210007A patent/BE1029004B1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100291240A1 (en) * | 2009-05-13 | 2010-11-18 | Wyeth Llc | Method to Stabilize a Dietary Supplement to Facilitate Joint Health in Humans |
Non-Patent Citations (2)
Title |
---|
ABI ADEBOWALE ET AL: "The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs", BIOPHARMACEUTICS AND DRUG DISPOSITION., vol. 23, no. 6, 1 January 2002 (2002-01-01), US, pages 217 - 225, XP055579848, ISSN: 0142-2782, DOI: 10.1002/bdd.315 * |
DALIRFARDOUEI RAZIEH ET AL: "Molecular mechanisms and biomedical applications of glucosamine as a potential multifunctional therapeutic agent", LIFE SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 152, 21 March 2016 (2016-03-21), pages 21 - 29, XP029536292, ISSN: 0024-3205, DOI: 10.1016/J.LFS.2016.03.028 * |
Also Published As
Publication number | Publication date |
---|---|
BE1029004A1 (en) | 2022-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Abu Eid et al. | Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition | |
Michaeloudes et al. | Role of metabolic reprogramming in pulmonary innate immunity and its impact on lung diseases | |
Holvast et al. | Influenza vaccination in systemic lupus erythematosus: safe and protective? | |
Stokes et al. | Post‐transplant bendamustine reduces Gv HD while preserving GvL in experimental haploidentical bone marrow transplantation | |
Elsaid et al. | Biobran/MGN-3, an arabinoxylan rice bran, enhances NK cell activity in geriatric subjects: A randomized, double‑blind, placebo-controlled clinical trial | |
Zhamanbaeva et al. | Antitumor activity of ethanol extract from Hippophae rhamnoides L. leaves towards human acute myeloid leukemia cells in vitro | |
BE1029004B1 (en) | New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseases | |
Cuthbertson et al. | Purinergic signalling in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease | |
Ou et al. | Dryocrassin ABBA, a novel active substance for use against amantadine-resistant H5N1 avian influenza virus | |
Gourin et al. | Anti-CMV therapy, what next? A systematic review | |
Smee et al. | Anti‐cowpox Virus Activities of Certain Adenosine Analogs, Arabinofuranosyl Nucleosides, and 2′‐Fluoro‐arabinofuranosyl Nucleosides | |
Kumari et al. | Withaferin A protects against primary and recurrent tuberculosis by modulating Mycobacterium-specific host immune responses | |
Liu et al. | Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease | |
Schell et al. | Dendritic cell migration limits the duration of CD8+ T-cell priming to peripheral viral antigen | |
Abramets et al. | Researches of the imidazole and indole derivatives cerebroprotective activity and its impact on effects of antidepressants | |
Pietrobon et al. | Antiviral response induced by toll-like receptor (TLR) 7/TLR8 activation inhibits human immunodeficiency virus type 1 infection in cord blood macrophages | |
Osidak et al. | Efficacy of the Inosine pranobex molecule in therapeutic and pediatric practice | |
Agrawal et al. | Biobran/MGN-3, an Arabinoxylan Rice Bran, Exerts Anti-COVID-19 Effects and Boosts Immunity in Human Subjects. Nutrients 2024, 16, 881 | |
Saxena et al. | 3170–TRACKING DEVELOPMENT OF RUNX1+ HEMOGENIC ENDOTHELIUM IN VITRO | |
Wollmann et al. | Replicative potency of oncolytic VSV-GP differentially shapes the immune signature in three distinct syngeneic tumour models | |
ЯРОВЕНКО | FEATURES OF NUCLEAR FRAGMENTATION DNA OF LIVER CELLS IN RATS ІN CHRONIC ALCOHOL INTOXICATION AND CONDITIONS OF QUERCETIN AND L-ARGININE L-GLUTAMATE | |
Arumimbang | MORALE VALUE IN MENDUNG KESAPUT ANGIN NOVEL BY AG SUHARTI | |
王雨 et al. | 34.5 BP is a new cellular target for Herpes Simplex Virus virulence factor ICP34. 5 anresponsible for virus-mediated effect on host gene splicing | |
Alisi et al. | Daclatasvir: a promising triple therapy for children with chronic hepatitis C | |
曹燕华 et al. | Interleukin-27 inhibits Hepatitis B virus replication mediated with the induction of interleukin-29 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Effective date: 20220816 |
|
MM | Lapsed because of non-payment of the annual fee |
Effective date: 20230131 |